Pharmaceutical Industry Reports Crohn's Disease Treatment Market | Page 2

REPORT DESCRIPTION
Crohn's Disease Treatment Market – Overview
According to the journal of Gastroenterology’s on Inflammatory Bowel Disease (IBD) in 2017, around 1.6 million patient
in the U.S were suffering from of IBD, out of which considerable section belongs to Crohn’s disease. Additionally, fast-
track drug approval application of FDA pertaining to treatments for Crohn’s disease is also expected to foster the market
in the forecast years.
The pipeline drugs offering innovative treatment solutions expecting to receive marketing approvals are anticipated to
propel the market growth. For instance, launch of interleukin (IL) inhibitor and anti-integrin therapy for Crohn’s disease,
risankizumab, is in the Phase III clinical trials of FDA developed by AbbVie and is expected to complete its trials by
January 2022. However, lack of awareness regarding available treatment options is expected to act as hindrance in the
market growth.
Moreover, development of new and effective therapy options to cure the symptoms of the disease is also a vital factor
contributing to the growth of Crohn’s disease treatment market. For instance, researchers from University of Washington
Medicine at the Crohn's & Colitis Congress held in January 2018 presented a study that developed an antibiotic that
showed four fold better response on the inflammation of intestine among patients suffering with Crohn’s disease as
compared to the existing therapies available in the market.